- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05062070
Safety and Efficacy of Topical TolaSure Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex (TAMES)
A Phase I/II, Closed Label, Randomized, Pilot Study for the Safety and Efficacy of TolaSure Gel, 5% w/w Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex (TAMES)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a closed-label, randomized, double-blind, Phase I clinical study to assess the safety and tolerability of the investigational product (IP), TolaSure Gel, 5% w/w, in patients diagnosed with severe epidermolysis bullosa simplex (EBS, previously known as EBS-Dowling Meara). Each patient (5 to complete) will apply TolaSure Gel, 5% w/w and TolaSure Vehicle Gel once-daily to defined Treatment Areas and Suction Blister Areas. End of Study (EOS) will occur at the Principal Investigator's (PI's) discretion according to the resolution or lack of improvement of the Treatment Areas. The maximum time a patient could be in the study is 10 weeks. The average time frame for each patient to complete the study is expected to be 6-8 weeks.
The primary safety endpoint will be the incidence of treatment-emergent adverse events (TEAEs). Safety monitoring will include physical exams, vital sign measurements, clinical laboratory testing (blood and urinalysis), and urine pregnancy testing (as appropriate).
Secondary efficacy endpoints will (1) assess wound severity within the Treatment Areas using an Investigator Global Assessment (IGA) scoring system, (2) examine under a microscope keratinocyte morphology and the incidence of keratin aggregates in Treatment Area skin biopsies, (3) determine the time required to induce a suction blister within the designated Suction Blister Areas, and (4) evaluate patient self-assessment of overall impression, pain, and itch within the Treatment Areas. The information obtained from these assessments will be used to examine the efficacy of TolaSure treatment in improving EBS symptoms.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Redwood City, California, United States, 94063
- Stanford University School of Medicine, Dermatology Department
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient is a male or female at least 18 years of age.
- Patient has a documented genetic mutation in either the keratin 14 (K14) or keratin 5 (K5) gene and that their EBS diagnosis and/or specific mutation are consistent with severe EBS (previously EBS-DM). (If severe EBS is suspected but not genetically confirmed, confirmatory testing will be performed).
Patient possesses the four required skin areas:
Treatment Areas:
- Must have two (2) Treatment Areas defined as an IGA score ≥ 3. Treatment Areas may have defined erosions, erythema, and ulcerations.
- Must be comparable in size with an area of approximately 300-400 cm^2 per area. Individually, a treatment area may be continuous or non-contiguous and must contain newly-formed blisters/erosions. Ideally, the two Treatment Areas on the patient should not be adjacent to each other and should be located bilaterally and roughly symmetrically on the trunk, abdomen, or upper or lower extremities.
- May not be infected (as assessed by the Principal Investigator) or have been treated with a topical antibiotic within 14 days.
- May not be located on palms, soles, scalp, groin, and any other areas that the Principal Investigator believes there will be difficulty in applying treatments and bandaging or assessing outcome measures.
Suction Blister Areas (SBAs):
- Must have two (2) areas of non-wounded and visually uninvolved skin, defined as an IGA score of zero (0).
- Must be comparable in size (approximately 50 cm^2)
If the patient is a woman of childbearing potential (WOCBP),
- Has a negative urine pregnancy test.
- Agrees to use an approved effective form of birth control with failure rates <1% per year (e.g., implant, injectable, combined oral contraceptive, intrauterine contraceptive device, sexual abstinence, vasectomized partner) during participation in the study (and at least 3 months thereafter).
- Is not nursing.
- Patient's laboratory values (blood and urine) are within the range of normal or abnormal values are within normal levels for the disease and in the opinion of the Principal Investigator the values are not clinically relevant for study participation.
- Patient is in good general health and free of any known disease state or physical condition which, in the Investigator's opinion, might impair evaluation of the EBS wounds or which exposes the patient to an unacceptable risk by study participation.
- Over the duration of the study, the patient agrees to not use any other topical therapies and/or impregnated dressings within the Treatment Areas or Suction Blister Areas (e.g., medicated cleansers, CBD oil, MediHoney, Silvadine cream 1%, topicals containing antimicrobials, keratin, and/or collagen, lipido-colloid or polymeric membrane dressings, and/or hydrogels).
- Patient must be able and willing to follow study procedures and instructions in order to maintain compliance throughout the study period.
- Patient has been informed, has read and understood the subject informed consent form, and has given written informed consent.
Exclusion Criteria:
Patient's use of prior or concomitant medication or medical treatments/procedures:
- Any investigational drug within 30 days.
- Systemic steroidal therapy within 30 days.
- Topical steroidal therapy within 14 days (Note: inhaled and ophthalmic products containing steroids are allowed).
- Systemic antibiotic therapy within 7 days.
- Systemic diuretics or cardiac glycosides within 30 days.
- Currently receiving chemotherapy or radiation.
- Patient has undergone stem cell transplant or gene therapy for the treatment of inherited EB.
- Surgery within the previous 3 months (except for minor cosmetic or dental procedures).
Patient's medical history includes:
- Cancer that is currently undergoing treatment.
- History of severe vitamin, mineral, or protein deficiency.
- Current systemic infection.
- HIV/AIDS.
- Non-EBS skin disease (e.g., psoriasis, atopic dermatitis, eczema, sun damage, etc.), or condition (e.g., sunburn) that, in the opinion of the Investigator, might put the subject at undue risk by study participation or interferes with the study medication application or the study assessments.
- An illness (e.g., neurological, cardiovascular, respiratory, hepatic, renal, or metabolic disease), condition, or situation that in the opinion of the Investigator is likely to interfere with the patient's participation in or completion of the study.
- Factors present in the patient and/or his/her legal representative that could interfere with study compliance such as inability to attend scheduled study visits or to perform study protocol procedures.
- Patient is a member of the investigational team or his/her immediate family.
- History of drug or alcohol abuse (as defined by the Investigator).
- Patient's use of smoking/vaping tobacco products.
- Other unspecified reasons that, in the opinion of the Investigator, make the subject unsuitable for enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 5 Percent TolaSure Topical Gel
5% (w/w) TolaSure Gel
|
TolaSure Topical Gel is applied once-daily for up to 10 weeks to designated Treatment Area and Suction Blister Area.
Other Names:
|
Placebo Comparator: Topical Vehicle Gel
TolaSure Vehicle Gel
|
TolaSure Vehicle Gel is applied once-daily for up to 10 weeks to designated Treatment Area and Suction Blister Area.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Time Frame: Day 1, Day 2, then Weekly until End of Study (maximum 10 weeks)
|
Safety monitoring will include clinical chemistry tests, physical examinations (including assessment of Treatment and Suction Blister Areas), and vital sign measurements.
These assessments along with AE reviews will identify potential TEAEs.
|
Day 1, Day 2, then Weekly until End of Study (maximum 10 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Investigator Global Assessment (IGA)
Time Frame: Day 1, Day 2, then Weekly until End of Study (maximum 10 weeks)
|
The Principal Investigator will use the IGA scale to score the average overall severity of the EBS wounds within the Treatment Areas, considered together.
Changes from baseline in IGA scores for the TolaSure-treated and Vehicle-treated Treatment Areas will be analyzed.
|
Day 1, Day 2, then Weekly until End of Study (maximum 10 weeks)
|
Keratin Aggregate Counts and Cell Morphology Assessment
Time Frame: Day 1, During Study (optional, estimated Week 3-Week 6), End of Study (maximum 10 weeks)
|
Biopsies from perilesional skin in each of the Treatment Areas are examined to determine a change from baseline in the number of keratin aggregate positive basal and suprabasal keratinocytes using transmission electron microscopy (TEM) and/or light microscopy.
|
Day 1, During Study (optional, estimated Week 3-Week 6), End of Study (maximum 10 weeks)
|
Suction Blister Time
Time Frame: Day 1 and End of Study (maximum 10 weeks)
|
A suction blister is raised within the Suction Blister Areas and the time to blister formation is recorded in seconds.
Changes from baseline suction blister times in the TolaSure-treated and Vehicle-treated Suction Blister Areas will be analyzed.
|
Day 1 and End of Study (maximum 10 weeks)
|
Patient's-reported Overall Impression Score of Treatment Areas
Time Frame: Day 1, then Weekly until End of Study (maximum 10 weeks)
|
Change from baseline in the patient-reported overall impression score of both the TolaSure-treated and Vehicle-treated Treatment Areas will be calculated.
|
Day 1, then Weekly until End of Study (maximum 10 weeks)
|
Patient's-reported Pain Score of Treatment Areas
Time Frame: Day 1, then Weekly until End of Study (maximum 10 weeks)
|
Change from baseline in the patient-reported pain numerical rating scale (NRS) of both the TolaSure-treated and Vehicle-treated Treatment Areas will be calculated.
|
Day 1, then Weekly until End of Study (maximum 10 weeks)
|
Patient's-reported Itch Score of Treatment Areas
Time Frame: Day 1, then Weekly until End of Study (maximum 10 weeks)
|
Change from baseline in the patient-reported itch numerical rating scale (NRS) of both the TolaSure-treated and Vehicle-treated Treatment Areas will be calculated.
|
Day 1, then Weekly until End of Study (maximum 10 weeks)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Keratinocytes containing Autophagosomes
Time Frame: Day 1, During Study (optional, estimated Week 3-Week 6), End of Study (maximum 10 weeks)
|
Biopsies from perilesional skin in each of the Treatment Areas are examined to determine a change from baseline in the number of autophagosome positive basal and suprabasal keratinocytes using transmission electron microscopy (TEM) and/or light microscopy.
|
Day 1, During Study (optional, estimated Week 3-Week 6), End of Study (maximum 10 weeks)
|
Cytokine Content in Suction Blister Fluid
Time Frame: Day 1 and End of Study (maximum 10 weeks)
|
Suction blister fluid collected from each of the induced suction blisters will be used to determine a change from baseline in inflammatory cytokine content.
|
Day 1 and End of Study (maximum 10 weeks)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TAMES-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epidermolysis Bullosa Simplex
-
Castle Creek Pharmaceuticals, LLCCompletedDystrophic Epidermolysis Bullosa | Epidermolysis Bullosa Simplex | Junctional Epidermolysis Bullosa | Epidermolysis Bullosa (EB)United States
-
TWi Biotechnology, Inc.RecruitingGeneralized Epidermolysis Bullosa SimplexTaiwan, Australia, Philippines
-
Centre Hospitalier Universitaire de NiceCompletedEpidermolysis Bullosa Simplex Dowling MearaFrance
-
Joyce TengRecruitingHealthy | Epidermolysis Bullosa | Genetic Skin Disease | Epidermolysis Bullosa Dystrophica | Epidermolysis Bullosa Simplex | Epidermolysis Bullosa, JunctionalUnited States
-
ProgenaBiomeRecruitingEpidermolysis Bullosa | Epidermolysis Bullosa Dystrophica | Epidermolysis Bullosa SimplexUnited States
-
InMed Pharmaceuticals Inc.CompletedEpidermolysis Bullosa Dystrophica | Epidermolysis Bullosa Simplex | Epidermolysis Bullosa, Junctional | Kindler SyndromeFrance, Germany, Greece, Israel, Italy
-
Castle Creek Pharmaceuticals, LLCTerminatedEpidermolysis Bullosa SimplexUnited States, Israel, Australia, Austria, France, Germany, Netherlands, United Kingdom
-
Tel-Aviv Sourasky Medical CenterUnknownEpidermolysis Bullosa Simplex
-
Castle Creek Pharmaceuticals, LLCCompletedEpidermolysis Bullosa | Epidermolysis Bullosa SimplexUnited States
-
Centre Hospitalier Universitaire de NiceUnknownEpidermolysis BullosaFrance
Clinical Trials on TolaSure Topical Gel
-
BioMendics, LLCSymbio, LLCCompletedWound HealingUnited States
-
BioMendics, LLCUniversity of MiamiCompletedWound HealingUnited States
-
Novan, Inc.CompletedAcne VulgarisUnited States
-
Glia, LLCCompletedContact Lens Discomfort | Contact Lens-induced Corneal Disorder | Contact Lens Acute Red Eye | Contact Lens-induced Corneal Fluorescein StainingUnited States
-
Rhodes Pharmaceuticals, L.P.ORA, Inc.Completed
-
Novan, Inc.CompletedAcne VulgarisUnited States
-
Maruho Co., Ltd.Leiden University Medical CenterCompletedCondylomata Acuminata (External)Netherlands
-
Maruho Co., Ltd.CompletedUsual Type Vulval Intraepithelial Neoplasia (uVIN)Netherlands
-
Maruho Co., Ltd.Completed
-
Maruho Co., Ltd.CompletedAcne VulgarisUnited States